Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes

Santella, Christina; Yin, Hui; Hicks, Blánaid; Yu, Oriana Hoi Yun; Bouganim, Nathaniel; Azoulay, Laurent

doi:10.1097/ede.0000000000001196

Cited by 5 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…49 Moreover, the weight-lowering effects of GLP-1RAs may increase BC incidence by easing the process of finding already present breast lumps, leading to early diagnosis of cancer. 19,28 Furthermore, postmenopausal women who lose weight over the long term have a lower risk of BC development. 50 The current study investigated the impact of incretinbased medication administration on BC incidence in women with T2DM using a meta-analysis of cohort studies.…”

Section: Discussionmentioning

confidence: 99%

“…To this end, four cohort studies were included: two studies found no association between incretins and BC incidence, one indicated protective roles against BC, and one showed an increase in BC detection with incretin-based therapies. 22,23,28,29 Due to the discordant results regarding the connection between incretins and BC, it was necessary to conduct a systematic review and meta-analysis of studies with longer-term follow-up.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incretin-Based Therapies and the Risk of Breast Cancer in Women with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Oladghaffari,

Rahnemayan,

Tohid

et al. 2023

Int J Drug Res Clin

View full text Add to dashboard Cite

Background: This systematic review and meta-analysis assessed the data from cohort studies that compared treatment with or without incretins and the incidence of breast cancer (BC) due to the current controversies. Methods: PubMed, Scopus, EMBASE, Cochrane, ProQuest, Ovid, and Google Scholar were searched for relevant studies. A secondary analysis was conducted to compare the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4Is) on BC development. Results: The meta-analysis of four studies with 58,767 patients and 461,475 controls revealed that incretin-based therapies increase the incidence of BC insignificantly (risk ratio (RR)=1.23, 95% confidence interval (CI)=0.44–3.40; P=0.69). The DPP-4I group significantly reduced the risk of BC compared to the GLP-1RA group (RR=0.43, 95% CI=0.32–0.59; P<0.00001). Conclusion: This study found no evidence of a substantial increase in BC incidence in patients with type 2 diabetes taking GLP-1RAs and DPP-4Is. However, DPP-4Is were less likely than GLP-1RAs to cause BC formation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Incretin-Based Therapies and the Risk of Breast Cancer in Women with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Oladghaffari,

Rahnemayan,

Tohid

et al. 2023

Int J Drug Res Clin

View full text Add to dashboard Cite

show abstract

“…Acute pancreatitis was rst reported in case reports in 2006 [11,12]. Additionally, the possible long-term effects of GLP-1RAs on pancreatic cancer were investigated [13,14]. A pharmacovigilance analysis based on the US Food and Drug Administration (FDA) adverse event reporting system suggested an increased risk of pancreatitis with GLP1RA when only exenatide was approved in the US [15].…”

Section: Introductionmentioning

confidence: 99%

Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a real-world pharmacovigilance study of post-marketing surveillance data

Pan

Tian

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background There are conflicting data on the potential risks of pancreatic carcinoma associated with glucagon-like peptide 1 receptor agonists (GLP-1RAs). Aim The study aimed to determine whether GLP-1RAs were associated with increased detection of pancreatic carcinoma based on the FDA Adverse Events Reporting System (FAERS) and clarify its potential mechanisms through keyword co-occurrence analysis. Method Disproportionality and Bayesian analyses were used for signal detection using reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayesian geometric mean (EBGM). Mortality, life-threatening events, and hospitalizations were also investigated. Keyword co-occurrence analysis of publications was adopted to uncover potential molecular mechanisms. Results A total of 3,073 pancreatic carcinoma cases were related to GLP-1RAs. Five GLP-1RAs were detected with signals for pancreatic carcinoma. Liraglutide had the strongest signal detection (ROR 54.45, 95% CI 51.21-57.90; PRR 52.52, 95%CI 49.49-55.73; IC 5.59; EBGM 48.30). The signals of exenatide (ROR 37.32, 95%CI 35.47-39.28; PRR 36.45, 95%CI 34.67-38.32; IC 5.00; EBGM 32.10) and lixisenatide (ROR 37.07, 95%CI 9.09-151.09; PRR 36.09; 95%CI 9.20-141.64; IC 5.17, EBGM 36.09) were stronger than those of semaglutide (ROR 7.43, 95%CI 5.22-10.57; PRR 7.39; 95%CI 5.20-10.50; IC 2.88, EBGM 7.38) and dulaglutide (ROR 6.47, 95%CI 5.56-7.54; PRR 6.45; 95%CI 5.54-7.51; IC 2.67, EBGM 6.38). The highest mortality rate occurred in exenatide (63.58%). cAMP/protein-kinase, Ca2+ channel, endoplasmic-reticulum stress, and oxidative stress are potential pathogenesis of pancreatic carcinoma resulted from GLP-1RAs. Conclusion GLP-1RAs, except albiglutide, are associatedwith pancreatic carcinoma based on the pharmacovigilance study.

show abstract

Highly selective detection of breast cancer cells mediated by multi-aptamer and dye-loaded mesoporous silica nanoparticles

Wang,

Chen

et al. 2024

Microchim Acta

View full text Add to dashboard Cite

Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes

Abstract: Weight-lowering effects of glucagon-like peptide-1 receptor agonists and detection of breast cancer among obese women with diabetes. Epidemiology.

Cited by 5 publications

References 40 publications

Incretin-Based Therapies and the Risk of Breast Cancer in Women with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Incretin-Based Therapies and the Risk of Breast Cancer in Women with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a real-world pharmacovigilance study of post-marketing surveillance data

Highly selective detection of breast cancer cells mediated by multi-aptamer and dye-loaded mesoporous silica nanoparticles

Contact Info

Product

Resources

About